CCT 251236

CAS : 1693731-40-6

Ref. 3D-BC168608

Informations sur le produit

• Nom: CCT 251236
• Synonymes: N-[5-[[(2,3-Dihydro-1,4-benzodioxin-6-yl)carbonyl]amino]-2-methylphenyl]-2-[2-(1-pyrrolidinyl)ethoxy]-6-quinolinecarboxamide
• Marque: Biosynth
• Description: CCT 251236 is a small molecule inhibitor of protein synthesis, which belongs to the class of heterobifunctional molecules. It is an orally administered drug with clinical relevance for cancer therapy. CCT 251236 is highly selective for eukaryotic protein synthesis, and has been shown to inhibit the proteasomal activity of the ribosome. This inhibition leads to a decrease in cellular protein content and disrupts protein homeostasis. CCT 251236 has been shown to be effective against primary cells in vitro, as well as in vivo in human clinical studies. CCT 251236 has also been shown to inhibit tumor growth by inducing cell cycle arrest and apoptosis.

Propriétés chimiques

• Masse moléculaire: 552.62 g/mol
• Formule: C₃₂H₃₂N₄O₅
• Degré de pureté: Min. 95%